Are you an advanced or metastatic Triple Negative Breast Cancer (TNBC) or platinum-resistant recurrent ovarian cancer (OC) patient? Stand Up To Cancer (SU2C) is supporting a clinical trial seeking a new immunology treatment.
Current treatment options are limited, and there is no approved “standard of care” (a treatment that is established as a best approach that a physician should use to treat these cancers).
Researchers on the SU2C-Ovarian Cancer Research Fund Alliance (OCRFA) – National Ovarian Cancer Coalition (NOCC) Ovarian Dream Team have evidence that there may be a connection between patients sensitive to one of two proteins, PD-1 immune checkpoints and PARP (an enzyme that helps repair DNA when it becomes damaged). The potential synergistic interaction between these proteins is at the heart of this clinical trial designed to evaluate a novel — or a first-of-its-kind — drug combination.
This clinical trial is integrated into the SU2C-OCRFA-NOCC Dream Team: DNA Repair Therapies for Ovarian Cancer research which seeks to bring new treatments to patients faster.